{"id":8323,"date":"2022-05-13T16:46:52","date_gmt":"2022-05-13T14:46:52","guid":{"rendered":"http:\/\/mohnfoundation.webforslag.com\/thematic-initiatives\/nasjonalt-forskningsprogram-pa-antibiotikaresistens-amr\/"},"modified":"2023-01-27T13:09:16","modified_gmt":"2023-01-27T12:09:16","slug":"national-research-programme-on-antimicrobial-resistance-amr","status":"publish","type":"page","link":"https:\/\/mohnfoundation.no\/en\/https-mohnfoundation-no-en-thematic-initiatives-womens-health\/national-research-programme-on-antimicrobial-resistance-amr\/","title":{"rendered":"National Research Programme on Antimicrobial Resistance (AMR)"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row css=&#8221;.vc_custom_1652453169926{margin-right: 0px !important;margin-left: 0px !important;background-image: url(https:\/\/mohnfoundation.no\/wp-content\/uploads\/2022\/05\/Fra-BFS-filmen-10-e1529573495180.jpg?id=629) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}&#8221;][vc_column]<div class=\"spacer-5830a5ea62c1f2880975a2ceab4a96be2\" style=\"\"><\/div><style>@media (min-width: 320px) { .spacer-5830a5ea62c1f2880975a2ceab4a96be2{ height: 200px;}}@media (min-width: 767px) { .spacer-5830a5ea62c1f2880975a2ceab4a96be2{ height: 200px;}}@media (min-width: 979px) { .spacer-5830a5ea62c1f2880975a2ceab4a96be2{ height: 400px;}}@media (min-width: 1200px) { .spacer-5830a5ea62c1f2880975a2ceab4a96be2{ height: 400px;}}<\/style>[\/vc_column][\/vc_row][vc_row el_class=&#8221;article-white&#8221; css=&#8221;.vc_custom_1649538946065{margin-right: 0px !important;margin-left: 0px !important;}&#8221;][vc_column][vc_row_inner css=&#8221;.vc_custom_1650537879673{margin-bottom: -30px !important;}&#8221;][vc_column_inner]<div class=\"header left  \"><h1 class=\"font-size-sm\" title=\"National Research Programme on Antimicrobial Resistance (AMR)\">National Research Programme on Antimicrobial Resistance (AMR)<\/h1><\/div>[\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=&#8221;2\/3&#8243;][vc_column_text]The Trond Mohn Foundation (TMF) wishes to contribute to increasing knowledge about antimicrobial resistance and has allocated NOK 106 million to a national research programme on antimicrobial resistance (AMR). Combined, the Universities of Oslo, Trondheim and Troms\u00f8, Stavanger University Hospital and Haukeland University Hospital will contribute an equally large amount to combating one of the biggest global and national threats to public health of our time.<\/p>\n<div class=\"wpb_text_column wpb_content_element \">\n<div class=\"wpb_wrapper\">\n<h3>Three topics: diagnostics, treatment, and monitoring<\/h3>\n<p>In June 2018, in cooperation with the Norwegian Institute of Public Health and other expert communities in Bergen, Stavanger, Oslo, Trondheim and Troms\u00f8, TMF launched a research programme focusing on the AMR issues that the expert communities themselves prioritise. The response to this initiative was excellent. TMF received as many as 16 project proposals that international experts have assessed as being of high quality, while at the same time reflecting the breadth, strength and substance of Norwegian research on antimicrobial resistance..<\/p>\n<p>In accordance with the experts\u2019 recommendations, NOK 75 million was awarded to four projects. The projects, which will have a duration of four years (2019\u20132023), cover the three topics in this initiative: treatment, diagnostics and monitoring. Host institutions in Troms\u00f8, Trondheim, Bergen and Oslo are engaged in the research. Universities coordinate three of the four projects, while Haukeland University Hospital will coordinate one project. Stavanger University Hospital, St. Olavs Hospital, Oslo University Hospital, the University Hospital of Northern Norway, Drammen Hospital and the University of Bergen are participating as partners. There are also some national partners, such as the Institute of Marine Research and the Norwegian Veterinary Institute. All the projects have international partners.<\/p>\n<h3>Four research projects:<\/h3>\n<h4><strong>Focus on pneumonia in the project managed from Bergen<\/strong><\/h4>\n<p>\u2018Paradoxically, antimicrobial resistance is partly caused by the health service itself. This is because incorrect use of antibiotics, for example where an antibiotic is used that does not \u201ctarget\u201d the microbe, is an important cause of the development of antimicrobial resistance,\u2019 say Professors Elling Ulvestad and Harleen Grewal of Haukeland University Hospital and the University of Bergen. They are conducting research on methods for arriving at faster and more precise diagnoses of respiratory tract infections.<\/p>\n<p>\u2018Pneumonia is one of the diseases where the use of antibiotics is too high, both in Norway and internationally. The reasons for this high consumption are that the disease is dangerous and that diagnosing it and identifying the pathogenic microbes involves difficult and time-consuming microbiology work. To ensure that patients recover, doctors therefore prescribe high doses of antibiotics, even for patients who do not need antibiotics. In the long term, this will prove to be a self-defeating strategy,\u2019 Ulvestad points out.<\/p>\n<p>The researchers will try to counteract the development of antimicrobial resistance by evaluating and developing new diagnostic tools, including a technological innovation \u2013 clinical metagenomics \u2013 which involves sequencing the genomes of the microbes.\u00a0 This could promote targeted and more correct use of antibiotics. In addition, the project will attempt to identify biomarkers that can help to indicate a prognosis for patients with pneumonia; endeavour to develop new diagnostic tools for identifying antimicrobial-resistant bacteria; optimise treatment protocols for pneumonia, and introduce new technologies that can help to detect and monitor antibiotic-resistant bacteria in people. \u2018We thereby hope to make an important contribution to developing the knowledge we need in the fight against antimicrobial resistance.\u2019<\/p>\n<p>The project is being carried out in close cooperation with the University of Bergen and Drammen Hospital. The international research collaboration includes leading research groups in Denmark, the Netherlands and the UK.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<h4><strong>The project managed from Trondheim aims to make it more difficult for bacteria to develop resistance to antibiotics<\/strong><\/h4>\n<p>In addition to reducing the use of antibiotics, it is important to develop new types of antibiotics that are effective against resistant bacteria and that can be combined with existing antibiotics. Under the leadership of Professor Marit Otterlei at the Norwegian University of Science and Technology (NTNU), an interdisciplinary team of researchers from the fields of microbiology, biology, chemistry and medicine is conducting research on several new antibiotics that can form the basis for the development of new drugs.<\/p>\n<p>Marit Otterlei says that the knowledge on which the development of these antibiotics is based comes from basic research on the maintenance of DNA and what mechanisms the bacteria use to develop resistance to antibiotics, i.e. how they mutate. \u2018These new antibiotic candidates attack bacteria in a completely different way from the antibiotics in use today, and they can potentially be developed into new antibiotics and be used to increase the effect of and counteract the development of resistance to current antibiotics,\u2019 she says.<\/p>\n<p>The project entails close cooperation between expert communities at NTNU, St. Olavs Hospital, Oslo University Hospital and Copenhagen University.<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>Focus on a critically important bacterium in the project coordinated from Troms\u00f8<\/strong><\/h4>\n<p>\u2018The project at the University of Troms\u00f8, which concerns the bacterium Klebsiella, is an opportunity for an outstanding team of researchers to study this group of bacteria in greater depth. Klebsiella has a key role in the global spread of antimicrobial resistance, and it is a target bacterium for innovative diagnostics, monitoring and alternative treatment.<\/p>\n<p>The World Health Organization (WHO) regards\u00a0<em>Klebsiella pneumoniae<\/em>\u00a0as a key factor in the global spread of antimicrobial-resistant pathogenic bacteria. WHO therefore classifies Klebsiella as a critically important target bacterium for research in the fight against antimicrobial resistance. The project is mapping the occurrence of and genetic relationship between Klebsiella in healthy and ill people and animals and in the environment in order to understand the importance of different reservoirs in the spread of antimicrobial-resistant pathogenic Klebsiella.<\/p>\n<p>\u2018This could form the basis for new diagnostic methods and targeted monitoring with a view to preventing the spread of, and infections caused by, particularly important groups of Klebsiella. \u00a0We are increasingly finding that we have no effective treatment alternatives against serious infections caused by multi-resistant Klebsiella. We will therefore also study the effect of bacteria viruses (bacteriaphages) on carriership and infections by antimicrobial-resistant Klebsiella as an alternative or supplement to antibiotics.<\/p>\n<p>This a multi-disciplinary and cross-sector project. It utilises Norway\u2019s unique infrastructure for monitoring antimicrobial resistance by using the Norwegian Surveillance System for Antimicrobial Drug Resistance (NORM), the Monitoring Program for Antimicrobial Resistance in the Veterinary and Food Production Sectors (NORM-VET), the Institute of Marine Research, the Norwegian Food Safety Authority and an established Norwegian and International network of researchers \u00a0(<a href=\"https:\/\/www.nor-kleb.net\/\" target=\"_blank\" rel=\"noopener\">www.nor-kleb.net<\/a>). The project is being led from UiT \u2013 The Arctic University of Norway in close cooperation with Stavanger University Hospital, and it involves four other Norwegian institutions: the Norwegian Veterinary Institute, the Institute of Marine Research, the University Hospital of Northern Norway and ACD Pharma (business partner). The international research collaboration includes leading research groups at Karolinska Institutet (Stockholm), Monash University (Melbourne), Queens University (Belfast) and Institut Pasteur (Paris).<\/p>\n<h4><strong>High-risk variants of E. coli bacteria in focus in the Oslo-led project<\/strong><\/h4>\n<p>Under the leadership of Professor Jukka Corander at the University of Oslo, researchers in Norway and abroad are studying E. coli, a bacterium that often causes infections in the blood and urinary tract and that is now proving resistant to antibiotics more often than before.<\/p>\n<p>The development of antimicrobial resistance is largely related to specific genetic variants (high-risk clones) in most bacteria species. These high-risk clones have now spread throughout the world.<\/p>\n<p>\u2018If we are to succeed in stopping the development and spread of antimicrobial resistance, we have to increase our understanding of how and why such high-risk clones arise and are spread,\u2019 says Professor Jukka Corander. \u2018In this project, we will focus on\u00a0<em>Escherichia coli<\/em>, which is the bacteria species that most often causes infections in the blood and urinary tract. The WHO has also defined E. coli as particularly important in relation to research on antibiotics and antimicrobial resistance.<\/p>\n<p>\u2018In the project, we are taking a system biology approach in order to understand what lies behind the selection, evolution and spread of high-risk\u00a0<em>E. coli<\/em>\u00a0clones. The objective of the project is to develop a basis for future risk assessments of existing and new bacteria clones, to improve monitoring and diagnostics, and to study new potential treatment strategies to limit the spread of antimicrobial resistance,\u2019 Corander says.<\/p>\n<p>The project is a collaborative project with UiT \u2013 The Arctic University of Norway and the Norwegian National Advisory Unit on Detection of Antimicrobial Resistance at the University Hospital of Northern Norway. The project also cooperates internationally with research groups at the University of Birmingham, UK and Houston Methodist Hospital in the USA.<\/p>\n<h3 id=\"tw-target-text\" class=\"tw-data-text tw-text-large XcVN5d tw-ta\" dir=\"ltr\" data-placeholder=\"Oversettelse\"><span class=\"Y2IQFc\" lang=\"en\">AMR-BRIDGE \u2013 a national collaborative project<\/span><\/h3>\n<p class=\"tw-data-text tw-text-large XcVN5d tw-ta\" dir=\"ltr\" data-placeholder=\"Oversettelse\"><span class=\"Y2IQFc\" lang=\"en\">AMR-Bridge will make the research results from the National Research Program on Antibiotic Resistance (AMR) available to other researchers and to the general public.<br \/>\n\u201cWe will facilitate the recruitment and development of new research talents, arrange academic hubs and take on the role of a hub in both dissemination and in an international research network on antibiotic resistance\u201d, says Arnfinn Sundsfjord, who leads the project. The project focuses on network building and dissemination and arranges, among other things, annual gatherings.<\/span><\/p>\n<h3 class=\"tw-data-text tw-text-large XcVN5d tw-ta\" dir=\"ltr\" data-placeholder=\"Oversettelse\"><span class=\"Y2IQFc\" lang=\"en\">\u00a0<\/span><\/h3>\n<p class=\"tw-data-text tw-text-large XcVN5d tw-ta\" dir=\"ltr\" data-placeholder=\"Oversettelse\"><span class=\"Y2IQFc\" lang=\"en\">The Trond Mohn Foundation funds also the <\/span><strong><span class=\"Y2IQFc\" lang=\"en\">CAMRIA <\/span><\/strong><span class=\"Y2IQFc\" lang=\"en\">(Combatting Anti-Microbial Resistance with Interdisciplinary Approaches) <\/span><span class=\"Y2IQFc\" lang=\"en\">center<\/span><span class=\"Y2IQFc\" lang=\"en\">, together with the University of Bergen, Haukeland University Hospital and Stavanger University Hospital. More information can be found <a href=\"https:\/\/mohnfoundation.no\/en\/camria_center\/\">here<\/a> and on the UiB <a href=\"https:\/\/camria.w.uib.no\/\" target=\"_blank\" rel=\"noopener\">webpage.<\/a><br \/>\n<\/span><\/p>\n<h3><em>Communication\/AMR-program in the media\u00a0\u00a0<\/em><\/h3>\n<p>2019: 7 February\u00a0<strong>Havforskningsinstituttet<\/strong>\u00a0<a href=\"https:\/\/www.hi.no\/hi\/nyheter\/2019\/februar\/skal-finne-ut-mer-om-problembakterie-som-ogsa-finnes-i-havet\" target=\"_blank\" rel=\"noopener\">Skal finne ut mer om problembakterie som ogs\u00e5 finnes i havet<\/a><br \/>\n2021: 24 September\u00a0<strong>Researchers night live<\/strong>,\u00a0<a href=\"https:\/\/www.ntnu.no\/forskningsdagene\/night\/live\" target=\"_blank\" rel=\"noopener\">Antibiotikaresistens krever ny forskning<\/a><br \/>\n2021: 5 July\u00a0<strong>Pestposten 2\/21<\/strong>\u00a0<a href=\"https:\/\/www.legeforeningen.no\/foreningsledd\/fagmed\/norsk-forening-for-infeksjonsmedisin\/aktuelt\/2021\/pest-posten-nr.-2-2021\/\" target=\"_blank\" rel=\"noopener\">APIM-peptidet<\/a><br \/>\n2021: 25 May\u00a0<strong>UiO.no<\/strong>\u00a0<a href=\"https:\/\/www.med.uio.no\/imb\/english\/research\/news-and-events\/news\/2021\/increase-in-antibiotic-resistant-e.coli-infections.html\" target=\"_blank\" rel=\"noopener\">Increase in antibiotic-resistant E.coli infections<\/a><br \/>\n2021: 12 May\u00a0<strong>Forskning.no<\/strong>\u00a0<a href=\"https:\/\/forskning.no\/bakterier-genteknologi-medisin-og-helse\/forskere-vet-na-mer-om-hvordan-antibiotikaresistens-utvikler-seg-i-norge\/1859705\" target=\"_blank\" rel=\"noopener\">Forskere vet n\u00e5 mer om hvordan antibiotikaresistens utvikler seg i Norge<\/a><br \/>\n2021: 11 May\u00a0<strong>Sanger Institute<\/strong>\u00a0<a href=\"https:\/\/www.sanger.ac.uk\/news_item\/identifying-the-rise-of-multi-drug-resistant-e-coli\/\" target=\"_blank\" rel=\"noopener\">Largest genomic study of\u00a0<i>E. coli<\/i>\u00a0has tracked the rise of multi-drug resistance (MDR) in Norway<\/a><\/p>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/3&#8243;]<div class=\"infobox light-brown\">\n<div>\n<div>\n<p>About the Programme<\/p>\n<\/div>\n<\/div>\n<div class=\"wpb_text_column wpb_content_element \">\n<div class=\"wpb_wrapper\">\n<p>Programme period: 2019-2025<br \/>\nTotal grant: 106 MNOK<\/p>\n<p>The projects:<\/p>\n<p>The Bergen-led project<\/p>\n<p>Title:\u00a0The Impact of Molecular Point-of-Care Testing and clinical metagenomics on Antibiotic Stewardship for acute respiratory infections (RESPNOR)<br \/>\nHost institution:\u00a0Haukeland University Hospital<br \/>\nPI:\u00a0Elling Ulvestad<br \/>\nTMF-grant:\u00a015,5 MNOK<\/p>\n<hr \/>\n<p><a href=\"https:\/\/www.ntnu.edu\/ikom\/tamir#\/view\/about\" target=\"_blank\" rel=\"noopener\">The Trondheim-led project<\/a><\/p>\n<p>Title:\u00a0Targeting AMR by inhibition of bacterial stress responses<br \/>\nHost institution:\u00a0Norwegian University of Science and Technology (NTNU)<br \/>\nPI:\u00a0Marit Otterlei<br \/>\nTMF-grant:\u00a020 MNOK<\/p>\n<hr \/>\n<p><a href=\"https:\/\/www.nor-kleb.net\/\" target=\"_blank\" rel=\"noopener\">The Troms\u00f8-led project<\/a><\/p>\n<p><em>Title:<\/em>\u00a0Klebsiella pneumoniae \u2013 a key driver in the global spread of antimicrobioal resistance and a target for new approaches in diagnostics, surveillance and alternative therapheutics (KLEB-GAP)<br \/>\n<em>Host institution:<\/em>\u00a0UiT \u2013 the Arctic University of Norway<br \/>\n<em>PI:<\/em>\u00a0Arnfinn Sundsfjord<br \/>\n<em>TMF-grant:<\/em>\u00a020 MNOK<\/p>\n<hr \/>\n<p>The Oslo-led project<\/p>\n<p>Title:\u00a0Battling Pandemic Multi-Drug Resistant E. coli Infections<br \/>\nHost institution:\u00a0University of Oslo<br \/>\nPI:\u00a0Jukka Corander<br \/>\nTMF-grant:\u00a019,5 MNOK<\/p>\n<hr \/>\n<p>National cooperative project \u2013 AMR-BRIDGE<\/p>\n<p>Title:\u00a0<a href=\"https:\/\/uit.no\/research\/amrbridge\" target=\"_blank\" rel=\"noopener\">AMR-BRIDGE \u2013 a common project to bridge and promote AMR-projects funded by TMF.\u00a0<\/a><br \/>\nHost institution:\u00a0University of Troms\u00f8<br \/>\nProject leader:\u00a0Arnfinn Sundsfjord<br \/>\nTMF-grant:\u00a05 MNOK<\/p>\n<hr \/>\n<p>Research center<\/p>\n<p>Title:\u00a0Combatting Anti-Microbial Resistance with Interdisciplinary Approaches \u2013 CAMRIA<br \/>\nHost institution:\u00a0University of Bergen<br \/>\nProject leader:\u00a0Nina Langeland<br \/>\nTMF-grant:\u00a07,7 MNOK<\/p>\n<hr \/>\n<p>Projects related to the CAMRIA center<\/p>\n<ul>\n<li><a href=\"https:\/\/camria.w.uib.no\/camria-media-and-amr\/\" target=\"_blank\" rel=\"noopener\">Risk communication and -perception of AMR in the public and among healthcare workers<\/a> (Media and AMR), PI Ingrid Smith, Haukeland University Hospital<\/li>\n<li><a href=\"https:\/\/camria.w.uib.no\/margin\/\" target=\"_blank\" rel=\"noopener\">Surveillance and Metagenomic tracking of Antimicrobial Resistance Genes IN environmental and clinical samples using machine learning approaches<\/a> (MARGIN), PI Randi Bertelsen, University of Bergen<\/li>\n<li><a href=\"https:\/\/camria.w.uib.no\/hyperevol\/\" target=\"_blank\" rel=\"noopener\">Learning and predicting the pathways of AMR evolution with hypercubic inference<\/a> (HyperEvol), PI Iain Johnston, University of Bergen<\/li>\n<\/ul>\n<p>TMF-grant:\u00a018 MNOK<\/p>\n<\/div>\n<\/div>\n<\/div>[\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column]<div class=\"spacer-3ed3c4f3188960fecee6faed144db8791289\" style=\"\"><\/div><style>@media (min-width: 320px) { .spacer-3ed3c4f3188960fecee6faed144db8791289{ height: 30px;}}@media (min-width: 767px) { .spacer-3ed3c4f3188960fecee6faed144db8791289{ height: 30px;}}@media (min-width: 979px) { .spacer-3ed3c4f3188960fecee6faed144db8791289{ height: 60px;}}@media (min-width: 1200px) { .spacer-3ed3c4f3188960fecee6faed144db8791289{ height: 60px;}}<\/style>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row css=&#8221;.vc_custom_1652453169926{margin-right: 0px !important;margin-left: 0px !important;background-image: url(https:\/\/mohnfoundation.no\/wp-content\/uploads\/2022\/05\/Fra-BFS-filmen-10-e1529573495180.jpg?id=629) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}&#8221;][vc_column][\/vc_column][\/vc_row][vc_row el_class=&#8221;article-white&#8221; css=&#8221;.vc_custom_1649538946065{margin-right: 0px !important;margin-left: 0px !important;}&#8221;][vc_column][vc_row_inner css=&#8221;.vc_custom_1650537879673{margin-bottom: -30px !important;}&#8221;][vc_column_inner][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=&#8221;2\/3&#8243;][vc_column_text]The Trond Mohn Foundation (TMF) wishes to contribute to increasing knowledge about [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary vidiflex-read-more-link\" href=\"https:\/\/mohnfoundation.no\/en\/https-mohnfoundation-no-en-thematic-initiatives-womens-health\/national-research-programme-on-antimicrobial-resistance-amr\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":8283,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"class_list":["post-8323","page","type-page","status-publish","hentry"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-22 21:46:19","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/pages\/8323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/comments?post=8323"}],"version-history":[{"count":8,"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/pages\/8323\/revisions"}],"predecessor-version":[{"id":9633,"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/pages\/8323\/revisions\/9633"}],"up":[{"embeddable":true,"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/pages\/8283"}],"wp:attachment":[{"href":"https:\/\/mohnfoundation.no\/en\/wp-json\/wp\/v2\/media?parent=8323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}